Fiche publication


Date publication

mars 2023

Journal

BMC cardiovascular disorders

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick


Tous les auteurs :
H Brandt-Jacobsen N, Johansen ML, Rasmussen JJ, Dalsgaard M, Kumler T, Faber J, Rossignol P, Schou M, Kistorp C

Résumé

Early heart failure prevention is central in patients with type 2 diabetes, and mineralocorticoid receptor antagonists (MRAs) have shown to improve prognosis. We investigated the effect of high-dose MRA, eplerenone, on cardiac function and structure in patients with type 2 diabetes and established or increased risk of cardiovascular disease but without heart failure.

Mots clés

Global longitudinal strain, High-dose eplerenone, Mineralocorticoid receptor antagonist, Systolic and diastolic function

Référence

BMC Cardiovasc Disord. 2023 03 31;23(1):175